Population and background
The study population had previously treated metastatic melanoma; it did not include every melanoma patient.
What the evidence shows
The ipilimumab study reported a survival difference compared with the study control, providing historical evidence for understanding CTLA-4 immunotherapy.
Conclusions that cannot be drawn
This international study was published in 2010 and applies to its enrolled population. It cannot establish the same outcome for an individual or replace comparison of current options.
Questions to ask your doctor
Is my previous treatment similar to this study population? Which current immunotherapies or other options can be compared, and how do their main risks differ?